This inhibitory effect was exerted through adiponectin and TNFα and was seen to be independent of VEGF.[6] In humans, the administration of FGF21 increases adiponectin in a dose-dependent form.[13] Low levels of adiponectin in human blood circulation may be associated with neovascularization-related diseases in the eyes.[14,15] Our results are consistent with the protective effects of this factor in neovascularization-related eye diseases, as described by previous studies. Here, ADIPOQ is linked to eye disorder.